Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
ENTAthis companyEnanta Pharmaceuticals, Inc.	$11.46	-3.12×	3.95×	3.91×	-5.99×	-669.1%	93.0%	-130.7%	-125.4%	-126.5%	-31.4%	-12.6%	3.11×	-2.38×	-11.11×	4.21×	0.0%	3	-0.92	1	C-
ASMBAssembly Biosciences, Inc.	$21.12	-61.84×	1.84×	5.27×	-54.31×	-382.4%	99.8%	-16.8%	-8.5%	-3.0%	-5.8%	-10.8%	0.01×	9.31×	0×	5.22×	0.0%	2	7.22	2	B-
AVIRAtea Pharmaceuticals, Inc.	$4.40	-1.84×	1.06×	0×	-1.19×	-75.3%	0.0%	0.0%	0.0%	-57.5%	-63.0%	-45.4%	0×	0.58×	0×	7.82×	0.0%	2	1.99	3	B-
CRBUCaribou Biosciences, Inc.	$0.45	-1×	1.22×	13.31×	-1.13×	-908.6%	67.3%	-1220.5%	-1327.4%	-121.2%	-89.8%	-75.7%	0.22×	-0.1×	0×	5.71×	0.0%	3	-7.25	2	C
FHTXFoghorn Therapeutics Inc.	$1.98	-4.58×	-3.13×	11×	-4.24×	-713.4%	89.2%	-265.6%	-240.3%	68.5%	-58.9%	-25.3%	-0.38×	0.56×	0×	2.73×	0.0%	3	-4.44	2	C
IMRXImmuneering Corporation	$3.62	-5.18×	1.33×	0×	-2.96×	-19.7%	0.0%	0.0%	0.0%	-25.6%	-26.7%	-15.7%	0.02×	2.24×	0×	17.5×	0.0%	0	6.81	2	B-
Peer median	—	-4.58×	1.22×	5.27×	-2.96×	-382.4%	67.3%	-16.8%	-8.5%	-25.6%	-58.9%	-25.3%	0.01×	0.58×	0×	5.71×	0.0%	2	1.99	2	—